Recruiting
Phase 2

Darolutamide

Sponsor:

National Cancer Institute (NCI)

Code:

NCT05669664

Conditions

Locally Advanced Salivary Gland Carcinoma

Metastatic Salivary Gland Carcinoma

Recurrent Salivary Gland Carcinoma

Unresectable Salivary Gland Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Darolutamide

Leuprolide Acetate

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-05-28.